The Efficacy of L-cysteine in Prevention of Cluster Headache

NCT02310828 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-17

No results posted yet for this study

Summary

The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort) the attacks of cluster headache.

Conditions

  • Cluster Headache

Interventions

DRUG

Acetium

Capsule for oral administration contains L-cysteine 100mg

DRUG

Placebo

A placebo capsule matching Acetium for oral administration.

Sponsors & Collaborators

  • The Finnish Funding Agency for Technology and Innovation (TEKES)

    collaborator OTHER_GOV
  • Biohit Oyj

    lead INDUSTRY

Principal Investigators

  • Mikko Kallela, MD, PhD · Helsinki Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-17
Primary Completion
2019-02-08
Completion
2020-10-14

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02310828 on ClinicalTrials.gov